{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:26:33Z","timestamp":1773282393126,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jsat.2020.108196","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T07:43:11Z","timestamp":1605339791000},"page":"108196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?"],"prefix":"10.1016","volume":"122","author":[{"given":"Edward V.","family":"Nunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances R.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muredach P.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabila","family":"El-Bassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2020.108196_bb0005","author":"American Medical Association"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2020.108196_bb0010","first-page":"S17","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2020.108196_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.ADM.0000435321.39251.d7","article-title":"Safe methadone induction and stabilization: Report of an expert panel","volume":"7","author":"Baxter","year":"2013","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2014A high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: Development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0030","article-title":"2019 National Survey on drug use and health (NSDUH)","author":"Center for Behavioral Health Statistics and Quality","year":"2020"},{"key":"10.1016\/j.jsat.2020.108196_bb0035","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: A randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2020.108196_bb0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: A 7-year cohort study","volume":"15","author":"Dupouy","year":"2017","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0045","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40263-019-00667-7","article-title":"Emergency department initiation of buprenorphine for opioid use disorder: Current status, and future potential","volume":"33","author":"Fox","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jsat.2020.108196_bb0050","unstructured":"Grimm, C.A. (2020). Geographic disparities affect access to buprenorphine services for opioid use disorder (No. OEI-12-17-00240). Office of the Inspector General. Jan 2020. p. 39."},{"key":"10.1016\/j.jsat.2020.108196_bb0055","doi-asserted-by":"crossref","unstructured":"Hser, Y.-I., Saxon, A.J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., Cohen, A., Ling, W. (2014). Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction (Abingdon, England), 109, 79\u201387. doi:https:\/\/doi.org\/10.1111\/add.12333.","DOI":"10.1111\/add.12333"},{"key":"10.1016\/j.jsat.2020.108196_bb0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0065","first-page":"e95","article-title":"Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?","volume":"64","author":"Kurdyak","year":"2018","journal-title":"Canadian Family Physician"},{"key":"10.1016\/j.jsat.2020.108196_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.jsat.2020.108196_bb0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/10826084.2017.1325376","article-title":"Primary care physicians\u2019 views about prescribing methadone to treat opioid use disorder","volume":"53","author":"Livingston","year":"2018","journal-title":"Substance Use and Misuse"},{"key":"10.1016\/j.jsat.2020.108196_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2020.108196_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2015.08.037","article-title":"The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting","volume":"156","author":"Nolan","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2020.108196_bb0095","unstructured":"Opioid Response Network [WWW Document], n.d. Opioid Response Netw. STR-TA. URL opioidresponsenetwork.org."},{"key":"10.1016\/j.jsat.2020.108196_bb0100","unstructured":"PCSSnow [WWW Document], n.d. Provid. Clin. Support Syst. URL PCSSnow.org."},{"key":"10.1016\/j.jsat.2020.108196_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5055\/jom.2012.0093","article-title":"Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters","volume":"8","author":"Quest","year":"2012","journal-title":"Journal of Opioid Management"},{"key":"10.1016\/j.jsat.2020.108196_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drugalcdep.2009.11.008","article-title":"Mortality among drug users after discharge from inpatient treatment: An 8-year prospective study","volume":"108","author":"Ravndal","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2020.108196_bb0115","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/ADM.0000000000000685","article-title":"Innovation during COVID-19: Improving addiction treatment access","volume":"14","author":"Samuels","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes","volume":"132","author":"Schuman-Olivier","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2020.108196_bb0125","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0130","first-page":"A24","article-title":"The most patriotic thing you can do right now","author":"The Editorial Board","year":"2020","journal-title":"New York Times"},{"key":"10.1016\/j.jsat.2020.108196_bb0135","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics","author":"Volkow","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0140","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMp1917360","article-title":"Stigma and the toll of addiction","volume":"382","author":"Volkow","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2020.108196_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2020.108196_bb0150","article-title":"COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States","author":"Wang","year":"2020","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jsat.2020.108196_bb0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/ajad.12805","article-title":"Expanding access to buprenorphine treatment in rural areas with the use of telemedicine: Buprenorphine in rural areas with telemedicine","volume":"27","author":"Weintraub","year":"2018","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2020.108196_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a cascade of care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"American Journal of Drug and Alcohol Abuse"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220304530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220304530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:00Z","timestamp":1760039580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547220304530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":32,"alternative-id":["S0740547220304530"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108196","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108196"}}